Table 2

Distribution of the study variables in patients with carbapenem resistant and carbapenem susceptible Acinetobacter baumannii infections
Variable Carbapenem-Resistant (total = 18) Carbapenem-Susceptible (total = 31) p
n = 18 (%) n = 31 (%)
Male sex 8 (44) 21 (68) 0.11
Agea 48 (28–63) 48 (37–58) 0.94
Infection acquired in the ICU 11 (61) 13 (42) 0.20
Previous use of any antibiotic b 14 (88) 8 (33) 0.001
Previous use of carbapenem b 10 (63) 1 (4) <0.001
Non-urinary site of infection 14 (78) 21 (68) 0.45
 Primary bacteremia 5 (28) 12 (39)
 Pneumonia 6 (33) 7 (23)
 Surgical site infection 3 (17) 2 (6)
Bacteremia c 9 (50) 19 (61) 0.44
Central venous catheter 16 (89) 15 (48) 0.005
Mechanical ventilation 12 (67) 13 (42) 0.10
Serum creatinine (μmol/L) a 200 (110 – 290) 230 (110–460) 0.39
Hemodialysis 8 (44) 4 (13) 0.01
Therapy for acute graft rejection 2 (11) 10 (32) 0.10
Septic shock 8 (44) 7 (23) 0.11
Appropriate empiric therapy for A. baumannii infection 10 (56) 19 (61) 0.69

ICU – intensive care unit; a median(interquartile range); b data available in 40 patients; c includes 11 cases of secondary bacteremia.

de Gouvêa et al.

de Gouvêa et al. BMC Infectious Diseases 2012 12:351   doi:10.1186/1471-2334-12-351

Open Data